This research study is studying Nintedanib dry powder inhalation (DPI) as a possible treatment for Idiopathic Pulmonary Fibrosis (IPF).
The purpose of this study is to learn if taking multiple doses of nintedanib DPI is safe and well-tolerated in people who have IPF. This study also aims to find the highest dose people can take without serious side effects. It will also measure how much of the study drug is in the blood at different dose levels.
STUDY DESIGN
If you qualify to take part in this study, you may participate in 1 of 2 groups:
• Group 1: 2 mg of nintedanib DPI or placebo (an inactive substance), taken three times a day
• Group 2: 4 mg of nintedanib DPI or placebo, taken twice a day
Contact us to learn more and see if you pre-qualify!